Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700327 | 0.82 | ECE1 (0.39) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18908668 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL25602347 | 0.82 | TP53 (0.47) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL24711403 | 0.81 | ECE1 (0.52) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL25602361 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL15071678 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL97236 | 0.79 | — | — | |
| SCHEMBL26733437 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18716191 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL17447544 | 0.78 | PSMB5 (0.53) | SMN1; SMN2TP53HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780935-B2 | Mutant antibodies and conjugation thereof | PFIZER HEALTHCARE IRELAND (IE) | 2023-10-10 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8741291-B2 | Multifunctional antibody conjugates | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-06-03 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2012-08-09 | — | — | US | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | SMN1; SMN2 3228/4885TP53 450/4885HPGD 2506/4885 |
| US-11780935-B2 | Mutant antibodies and conjugation thereof | IGLV6-57, IGSF11, F13B | SMN1; SMN2 2832/4885TP53 1347/4885HPGD 4291/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | SMN1; SMN2 866/4885TP53 651/4885HPGD 1818/4885 |
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | SMN1; SMN2 3869/4885TP53 2951/4885HPGD 2008/4885 |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | SMN1; SMN2 3069/4885TP53 444/4885HPGD 2530/4885 |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | CLTB, CLTA, FCGRT | SMN1; SMN2 4593/4885TP53 2397/4885HPGD 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.